- Home
- CRGX vs MAX Comparison
CRGX vs MAX Comparison
Compare CRGX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- MAX
- Stock Information
- Founded
- CRGX 2021
- MAX 2014
- Country
- CRGX United States
- MAX United States
- Employees
- CRGX N/A
- MAX N/A
- Industry
- CRGX
- MAX Industrial Machinery/Components
- Sector
- CRGX
- MAX Industrials
- Exchange
- CRGX Nasdaq
- MAX Nasdaq
- Market Cap
- CRGX 628.6M
- MAX 604.9M
- IPO Year
- CRGX 2023
- MAX 2020
- Fundamental
- Price
- CRGX $3.70
- MAX $11.77
- Analyst Decision
- CRGX Hold
- MAX Buy
- Analyst Count
- CRGX 7
- MAX 8
- Target Price
- CRGX $4.67
- MAX $22.00
- AVG Volume (30 Days)
- CRGX 1.9M
- MAX 375.8K
- Earning Date
- CRGX 03-20-2025
- MAX 02-24-2025
- Dividend Yield
- CRGX N/A
- MAX N/A
- EPS Growth
- CRGX N/A
- MAX N/A
- EPS
- CRGX N/A
- MAX 0.19
- Revenue
- CRGX N/A
- MAX $681,230,000.00
- Revenue This Year
- CRGX N/A
- MAX $122.48
- Revenue Next Year
- CRGX N/A
- MAX $32.24
- P/E Ratio
- CRGX N/A
- MAX $62.34
- Revenue Growth
- CRGX N/A
- MAX 72.47
- 52 Week Low
- CRGX $3.00
- MAX $10.21
- 52 Week High
- CRGX $33.92
- MAX $25.78
- Technical
- Relative Strength Index (RSI)
- CRGX 20.88
- MAX 55.43
- Support Level
- CRGX $3.00
- MAX $11.02
- Resistance Level
- CRGX $3.88
- MAX $11.73
- Average True Range (ATR)
- CRGX 0.92
- MAX 0.45
- MACD
- CRGX -1.00
- MAX 0.09
- Stochastic Oscillator
- CRGX 5.99
- MAX 75.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.